Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David DeMets

Showing results (21-30 of 51) with videos related to

Pageof 6
Sort By:
Clinical Trials (London, England)|May 16, 2017
Recommendations for data monitoring committees from the Clinical Trials Transformation InitiativeKarim A Calis, Patrick Archdeacon, Raymond Bain, et al.
JACC. Heart Failure|February 11, 2019
Impact of Degree of Left Ventricular Remodeling on Clinical Outcomes From Cardiac Resynchronization TherapyFadi Shamoun, Teresa De Marco, David DeMets, et al.
Clinical Trials (London, England)|August 24, 2007
Monitoring the randomized trials of the Women's Health Initiative: the experience of the Data and Safety Monitoring BoardJanet Wittes, Elizabeth Barrett-Connor, Eugene Braunwald, et al.
Investigational New Drugs|October 28, 2003
Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancerGlenn Liu, Kurt Oettel, Howard Bailey, et al.
JACC. Heart Failure|April 29, 2017
Long-Term Effect of Endothelin Receptor Antagonism With Bosentan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure: Primary Results of the ENABLE TrialsMilton Packer, John J V McMurray, Henry Krum, et al.
The New England Journal of Medicine|May 21, 2004
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failureMichael R Bristow, Leslie A Saxon, John Boehmer, et al.
Clinical Trials (London, England)|November 12, 2005
Issues in regulatory guidelines for data monitoring committeesDavid DeMets, Robert Califf, Dennis Dixon, et al.
Circulation|February 11, 2009
Cardiac resynchronization therapy reduces the risk of hospitalizations in patients with advanced heart failure: results from the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) trialInder S Anand, Peter Carson, Elizabeth Galle, et al.
Circulation|March 5, 2013
Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA guideline recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice GuidelinesJeffrey L Anderson, Jonathan L Halperin, Nancy M Albert, et al.
European Journal of Heart Failure|May 29, 2021
Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trialScott D Solomon, Rudolf A de Boer, David DeMets, et al.
Pageof 6

Showing results (21-30 of 51) with videos related to

Sort By:
Pageof 6
Clinical Trials (London, England)|May 16, 2017
Recommendations for data monitoring committees from the Clinical Trials Transformation InitiativeKarim A Calis, Patrick Archdeacon, Raymond Bain, et al.
JACC. Heart Failure|February 11, 2019
Impact of Degree of Left Ventricular Remodeling on Clinical Outcomes From Cardiac Resynchronization TherapyFadi Shamoun, Teresa De Marco, David DeMets, et al.
Clinical Trials (London, England)|August 24, 2007
Monitoring the randomized trials of the Women's Health Initiative: the experience of the Data and Safety Monitoring BoardJanet Wittes, Elizabeth Barrett-Connor, Eugene Braunwald, et al.
Investigational New Drugs|October 28, 2003
Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancerGlenn Liu, Kurt Oettel, Howard Bailey, et al.
JACC. Heart Failure|April 29, 2017
Long-Term Effect of Endothelin Receptor Antagonism With Bosentan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure: Primary Results of the ENABLE TrialsMilton Packer, John J V McMurray, Henry Krum, et al.
The New England Journal of Medicine|May 21, 2004
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failureMichael R Bristow, Leslie A Saxon, John Boehmer, et al.
Clinical Trials (London, England)|November 12, 2005
Issues in regulatory guidelines for data monitoring committeesDavid DeMets, Robert Califf, Dennis Dixon, et al.
Circulation|February 11, 2009
Cardiac resynchronization therapy reduces the risk of hospitalizations in patients with advanced heart failure: results from the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) trialInder S Anand, Peter Carson, Elizabeth Galle, et al.
Circulation|March 5, 2013
Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA guideline recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice GuidelinesJeffrey L Anderson, Jonathan L Halperin, Nancy M Albert, et al.
European Journal of Heart Failure|May 29, 2021
Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trialScott D Solomon, Rudolf A de Boer, David DeMets, et al.
Pageof 6